In Alzheimer’s diseases (AD), tau pathology is strongly associated with cognitive decline.
Preclinical evidence suggests that tau spreads across connected neurons in an activity-…

In Alzheimer’s disease (AD), the Braak staging scheme suggests a stereotypical tau spreading
pattern that does, however, not capture interindividual variability in tau deposition. This …

In Alzheimer’s disease, tau pathology spreads hierarchically from the inferior temporal lobe
throughout the cortex, ensuing cognitive decline and dementia. Similarly, circumscribed …

In Alzheimer’s disease (AD), younger symptom onset is associated with accelerated
disease progression and tau spreading, yet the mechanisms underlying faster disease …

Cognitive resilience is an important modulating factor of cognitive decline in Alzheimer’s
disease, but the functional brain mechanisms that support cognitive resilience remain elusive. …

Tau pathology is the main driver of neuronal dysfunction in 4-repeat tauopathies, including
cortico-basal degeneration and progressive supranuclear palsy. Tau is assumed to spread …

Microglial activation occurs early in Alzheimer's disease (AD) and previous studies reported
both detrimental and protective effects of microglia on AD progression. Here, we used CSF …

The single nucleotide polymorphism (SNP) rs744373 in the bridging integrator-1 gene (BIN1)
is a risk factor for Alzheimer’s disease (AD). In the brain, BIN1 is involved in endocytosis …

Background Tau-PET is a prognostic marker for cognitive decline in Alzheimer’s disease, and
the heterogeneity of tau-PET patterns matches cognitive symptom heterogeneity. Thus, tau…

Background To systematically examine the clinical utility of tau-PET and Braak-staging as
prognostic markers of future cognitive decline in older adults with and without cognitive …